Rheumatology International最新文献

{"title":"Diabetic foot in the context of rheumatic diseases: pathogenesis and treatment approaches.","authors":"Dana Bekaryssova, Marlen Yessirkepov, Ak-Uke Rakisheva, Assylkhan Bakytzhan","doi":"10.1007/s00296-025-05890-8","DOIUrl":"https://doi.org/10.1007/s00296-025-05890-8","url":null,"abstract":"<p><p>Diabetic foot is a frequent and debilitating complication of diabetes mellitus that significantly impairs quality of life and increases the risk of disability and amputation. This review examines the multifactorial pathogenesis of diabetic foot, focusing on its increased incidence and severity in patients with rheumatic diseases. The development of diabetic foot is driven by diabetic neuropathy, peripheral vascular disease, and infection. In patients with rheumatic diseases, chronic systemic inflammation and vascular dysfunction further accelerate tissue damage and impair wound healing. Long-term use of pharmacologic agents such as glucocorticoids and nonsteroidal anti-inflammatory drugs also contributes to metabolic imbalance, immune suppression, and vascular complications, increasing the risk of ulceration and infection. Rheumatic disease-related joint deformities and altered foot biomechanics add mechanical stress, exacerbating the condition. Effective management of diabetic foot in patients with rheumatic diseases requires a multidisciplinary approach. This includes early diagnosis, strict glycemic control, modulation of systemic inflammation, optimization of vascular health, and preventive foot care strategies. Addressing both metabolic and rheumatologic components is essential to reduce the risk of severe outcomes such as chronic infection and limb amputation. Understanding the interplay between diabetes and rheumatic diseases is crucial for improving clinical outcomes. Targeted, integrated interventions are key to preventing complications and enhancing the quality of life for affected patients.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"132"},"PeriodicalIF":3.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-TIF1-beta autoantibody-positive dermatomyositis: a case-based review.","authors":"Jean-Baptiste Vulsteke, Petra De Haes, Minoru Satoh, Ben Van Cleynenbreugel, Benoit Beuselinck, Xavier Bossuyt, Ellen De Langhe","doi":"10.1007/s00296-025-05886-4","DOIUrl":"https://doi.org/10.1007/s00296-025-05886-4","url":null,"abstract":"<p><p>To describe the clinical features and cancer risk in patients with dermatomyositis (DM) and anti-TIF1β autoantibodies without other DM-specific autoantibodies (anti-TIF1β-monospecific DM) through a case-based review. Case report of anti-TIF1β-monospecific cancer-associated DM and literature review of cases of anti-TIF1β-monospecific DM. We describe a case of a person with cancer-associated DM in whom we identified anti-TIF1β autoantibodies through immunoprecipitation-mass spectrometry. He had typical cutaneous involvement, mild myositis and a good response to medical therapy after curative treatment of an underlying renal cell cancer. A literature search of Pubmed and Scopus identified 9 more persons with anti-TIF1β-monospecific DM revealing a homogeneous phenotype with typical cutaneous involvement, mild to absent muscular involvement and absence of interstitial lung disease. Two out of ten (20%) had cancer-associated DM. Anti-TIF1β-monospecific DM represents a homogeneous subset of DM characterized by typical cutaneous involvement, mild to absent myositis and potentially an elevated cancer risk (20%). More cohort studies with adequate detection methods are needed to formally assess the cancer risk as compared to anti-TIF1γ and other DM-specific autoantibodies.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"131"},"PeriodicalIF":3.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current concepts on pathogenesis, diagnosis and management of hepatic sarcoidosis.","authors":"Nabil Belfeki, Sonia Kammoun, Nouha Ghriss, Charif Eldirani, Arsene Mekinian","doi":"10.1007/s00296-025-05888-2","DOIUrl":"https://doi.org/10.1007/s00296-025-05888-2","url":null,"abstract":"<p><p>Sarcoidosis is an inflammatory multisystemic granulomatosis of unknown cause, with a wide range of clinical features, characterized by the presence of non-caseating granulomas. Liver is the third involved organ after lungs and lymph nodes, with a reported prevalence of hepatic involvement in 5 to 25% of systemic symptomatic sarcoidosis. The immunopathogenesis of sarcoidosis is still unknown but it seems to involve the innate and adaptive immune actors in response to a putative antigen in genetically predisposed individuals. Because of its paucisymptomatic presentation, hepatic sarcoidosis may be underdiagnosed. Unspecified impaired general condition, fever, abdominal pain, and jaundice are the main symptoms associated with liver sarcoidosis. Frequently, laboratory liver tests are abnormal. Imaging tools may reveal liver nodular enlargement but can be totally normal. Liver biopsy is often required to confirm the diagnosis. A meticulous workup is mandatory to rule out differential diagnosis of hepatic granuloma. Portal hypertension and liver cirrhosis are the most prevalent complications of hepatic sarcoidosis. Treatment is not necessary in all cases and first line treatment in symptomatic patients requires corticosteroids and/or ursodeoxycholic acid. Immunosuppressants and biologics could be used as second line agents. In severe cases, liver transplantation is indicated.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"130"},"PeriodicalIF":3.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings.","authors":"Cay-Benedict von der Decken, Stefan Kleinert, Matthias Englbrecht, Kirsten Karberg, Georg Gauler, Monika Ronneberger, Praxedis Rapp, Florian Schuch, Joerg Wendler, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Martin Welcker, Peter Bartz-Bazzanella","doi":"10.1007/s00296-025-05861-z","DOIUrl":"https://doi.org/10.1007/s00296-025-05861-z","url":null,"abstract":"<p><p>More efficient means of identifying patients with inflammatory rheumatic diseases (IRDs) could allow earlier diagnosis and treatment. The objective of this study was to evaluate the characteristics of a revised version of an online patient questionnaire-based self-referral tool, RhePort 1.3. This prospective study included adult patients with musculoskeletal complaints presenting for a first rheumatology visit at German RheumaDatenRhePort (RHADAR) rheumatology network centers. All patients completed the RhePort 1.3 questionnaire on patient characteristics and symptoms. Data from RhePort 1.3 were compared with historical data from previous versions. Of 614 patients, 225 (36.6%) were diagnosed with an IRD by a rheumatologist and 164/225 IRD patients (72.9%) had a RhePort 1.3 score > 1, the cut-off point used to determine the need for rheumatologic evaluation. A score > 1 was associated with an approximately two-fold higher IRD risk (odds ratio [95% confidence interval] of 1.98 [1.39, 2.83] vs ≤ 1) and had good sensitivity (73%) and moderate specificity (42%). Among patients referred through a standard referral pathway (n = 283), RhePort 1.3 scores > 1 in addition to physician referral were associated with increases in rheumatology-diagnosed IRD rates from 33.2% (physician referral only) to 45.7%. RhePort 1.3 had higher accuracy than earlier versions (54% vs 35%). We conclude that modest changes to the RhePort questionnaire resulted in increased accuracy. A score > 1 was associated with a doubled risk for an IRD and higher IRD rates in physician-referred patients. These data suggest that RhePort has the potential to streamline the rheumatologist's workload and improve resource use. Further modifications are required to improve specificity.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"129"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depressive symptoms are highly prevalent and associated with fatigue and pain catastrophizing in the Hypermobility Spectrum Disorders and hypermobile Ehlers Danlos syndrome: a cross-sectional study.","authors":"Elizabeth Kathleen Stockton Fletcher, Ashley Loren Fischer, Ranita Harpreet Kaur Manocha","doi":"10.1007/s00296-025-05869-5","DOIUrl":"https://doi.org/10.1007/s00296-025-05869-5","url":null,"abstract":"<p><p>Individuals living with Hypermobility Spectrum Disorders and the hypermobile Ehlers-Danlos syndrome (HSD/hEDS) often experience recurrent joint injury, chronic pain, and fatigue. Although generalized anxiety has been recognized as a common comorbidity with HSD/hEDS, minimal research has examined depressive symptoms in this population. The purpose of this investigation was to describe the prevalence, nature, and severity of depressive symptoms in the HSD/hEDS population, and to explore associations with other potential confounding factors. All individuals with HSD/hEDS referred to a specialized connective tissue disorder Physical Medicine & Rehabilitation clinic were asked to self-report demographic data and complete the 9-item Patient Health Questionnaire (PHQ-9), 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), Pain Catastrophizing Symptoms (PCS) questionnaire, and Fatigue Severity Scale (FSS) at their initial clinic visit. Data was prospectively collected between January 2019 and December 2024. Descriptive statistics were performed. A Spearman correlation matrix was used to identify relevant factors associated with depressive symptoms. Relationships emerging as significant (p < 0.001) were further analyzed using independent sample Mann-Whitney U-tests. Fifty-nine individuals (53 female, mean ± SD age: 34.4 ± 11 years) were included, with a mean ± SD PHQ-9 score of 11.2 ± 5.9, indicating moderate depressive symptom severity. 53% of participants (n = 31) met criteria for major depressive disorder (PHQ-9 ≥ 10). Higher pain catastrophizing (ρ = 0.611, p < 0.001) and higher fatigue scores (ρ = 0.593, p < 0.001) were both associated with significantly higher depressive symptoms, but there were no associations with respect to age, working status, and number of alcoholic drinks consumed per week. This research suggests that depression is highly prevalent in patients experiencing HSD/hEDS. There is also a strong association between pain catastrophizing and fatigue in those experiencing depressive symptoms. The interaction between depressive symptoms, pain catastrophizing, and fatigue should be considered in the holistic management of HSD/hEDS.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"128"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of ≥ 10 years: a real-world evidence study.","authors":"Chrysanthi Staveri, Chrysa Lykoura, Konstantinos Melissaropoulos, Stamatis-Nick C Liossis","doi":"10.1007/s00296-025-05879-3","DOIUrl":"https://doi.org/10.1007/s00296-025-05879-3","url":null,"abstract":"<p><p>Treatment of Systemic Lupus Erythematosus (SLE) remains challenging. The aim of this real-world evidence study of patients with refractory SLE treated with rituximab (RTX) was to explore for any potential long-term effect(s) of this particular B cell depletion approach. This study included patients with SLE who had i) received at least 1 cycle of RTX and had ii) an at least 10 yr of follow-up after their first RTX infusion. Outcomes were assessed at 1 year and at their latest evaluation that was ≥ 10 yr after RTX treatment initiation. In cases where the SLE Disease Activity Index 2000 (cSLEDAI-2 k) was employed, a response was defined as a cSLEDAI-2 k of less than 4 in cases where the cSLEDAI-2 k was ≥ 4. In cases where the cSLEDAI-2 k was 2-4 at baseline, a response was defined as a cSLEDAI-2 k of 0. RTX was administered in 62 patients with SLE. For this real-world evidence study 23 patients (25 cases) with SLE (all Caucasian female, age range: 14-72 yr, mean: 31 yr) with active or relapsing disease, fulfilling inclusion criteria were enrolled. RTX treatment was associated with a response rate of 68.75% after 1 yr and 75% after ≥ 10 yr. The median cSLEDAI-2 K score decreased from 5.83 ± 3.70 at baseline to 1.95 ± 2.40 (p < 0.001) at 1 yr and to 2.37 ± 3.00 (p < 0.001) at the ≥ 10 yr time-point of follow-up. Our data suggest that RTX may indeed represent an alternative therapeutic option in patients with SLE refractory to standard treatment with an acceptable safety profile.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"127"},"PeriodicalIF":3.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender bias in Argentine rheumatology research: a bibliometric analysis.","authors":"Belén Navarro, Julieta Car, Gabriel Sequeira, Eduardo Mario Kerzberg","doi":"10.1007/s00296-025-05885-5","DOIUrl":"https://doi.org/10.1007/s00296-025-05885-5","url":null,"abstract":"<p><p>Despite growing female participation in the workforce, gender disparities persist across sectors. Little is known about how these manifest in academic rheumatology in Argentina. To analyze recently published rheumatology research by Argentine authors from a gender perspective. A bibliometric analysis was conducted on rheumatology publications from 2018 to 2022 in the Argentine Journal of Rheumatology (AJR) and PubMed-indexed journals that included at least one Argentine author. Argentine authors were classified by gender, and authorship roles (overall, first, and corresponding authors) were assessed, along with pharmaceutical industry conflicts of interest (COIs). Of 130 AJR articles (1183 Argentine authors), 61.8% were women. In 440 PubMed-indexed articles (1957 Argentine authors), 55.2% were women. Women were more frequently first authors in both AJR and PubMed (67.7% vs. 58.4%; p = 0.13), but less often corresponding authors in PubMed (44%) than in AJR (60%; p = 0.02). In AJR, female authors had a higher median number per article (3, Interquartile range or IQR 2-6) than male authors (2, IQR 1-4; p = 0.002). In PubMed, male authors showed slightly greater median participation (1, IQR 1-2 vs. 1, IQR 0-2; p = 0.02). In industry-sponsored studies, only 28.1% of authors were women. In COI-declaring publications, 71.0% listed only male disclosures; of 153 total reports, just 26.8% were by women. Although women are the majority in Argentine rheumatology research, they remain underrepresented in leadership roles and industry-funded studies. Continued monitoring of gender and COI data is needed.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"126"},"PeriodicalIF":3.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiogenic shock in systemic sclerosis: a retrospective study of acute ventricular dysfunction.","authors":"Aitor Uribarri, Alfredo Guillen-Del Castillo, Yassin Belahnech, Guillem Casas, Alejandra Gabaldón, Neus Bellera, Ruperto Oliveró, Toni Soriano-Colomé, Claudia Codina-Claveguera, José Rodriguez-Palomares, José A Barrabés, Ignacio Ferreira-González, Carmen P Simeon","doi":"10.1007/s00296-025-05874-8","DOIUrl":"https://doi.org/10.1007/s00296-025-05874-8","url":null,"abstract":"<p><p>Cardiac involvement in systemic sclerosis (SSc) is a major cause of morbidity and mortality, with ventricular dysfunction and cardiogenic shock being among the most severe complications. The underlying causes of acute ventricular dysfunction in these patients remain unclear. This observational study included 10 SSc patients admitted with cardiogenic shock and acute ventricular dysfunction between 2010 and 2023, excluding those with prior heart disease. Clinical, laboratory, imaging, and pathological data were analyzed, with outcomes assessed at six months. The cohort was 90% female, with a mean age of 58.8 ± 3.8 years. Most had diffuse cutaneous SSc (70%) and musculoskeletal involvement (50%), with an average disease duration of 4.8 ± 5.2 years. All patients presented with severe hemodynamic instability, with a mean systolic blood pressure of 78.4 ± 6.7 mmHg and elevated troponin levels (2077 ± 3379 ng/L). Pericardial effusion was observed in all, and 30% required pericardiocentesis. CMR showed presence of late gadolinium enhancement and prolonged T2 relaxation time and reduced ventricular function (LVEF 31 ± 8%). Biopsies revealed myocarditis with T lymphocyte and macrophage infiltration. In-hospital mortality was 60%. Among survivors, partial ventricular recovery was seen at six months, with an average LVEF improvement of 10 ± 10%. SSc patients with cardiogenic shock and acute ventricular dysfunction face high mortality and limited recovery. The phenotype is associated with diffuse cutaneous SSc and musculoskeletal involvement, likely driven by myocarditis, highlighting the need for improved cardiac-focused treatments in SSc.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"125"},"PeriodicalIF":3.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and clinical features of early axial spondyloarthritis according to ASAS definition: a cross-sectional analysis from the reuma-check cohort.","authors":"Rodrigo Garcia-Salinas, Nataly Mejia-Maggi, Felicia Almada, Sebastian Magri, Victoria Navarro-Compán","doi":"10.1007/s00296-025-05873-9","DOIUrl":"https://doi.org/10.1007/s00296-025-05873-9","url":null,"abstract":"<p><p>Objectives to estimate the prevalence at diagnosis of early axial spondyloarthritis in Argentinian Reuma-Check cohort, according to ASAS definition (early axSpA) and to identify clinical, laboratory, and imaging features associated with this group in a Latin American cohort. This single-center, observational, cross-sectional study included consecutive adult patients diagnosed with axSpA. Early axSpA was defined as ≤ 2 years of axial symptoms at diagnosis. Clinical, laboratory, and imaging assessments were performed following standardized protocols. A primary analysis was conducted on the entire cohort of diagnosed patients, followed by two subgroup analyses: one including only those fulfilling the ASAS 2009 criteria and another excluding patients with psoriasis. Logistic regression was conducted to identify factors independently associated with early axSpA. Among 124 patients, 38% (n = 47) had early axSpA at diagnosis. Significant differences between early and established axSpA included smoking habit (30 vs. 51%, p = 0.02), NSAID response (58 vs. 74%, p = 0.06), family history (38 vs. 23%, p = 0.04), and radiographic sacroiliitis (37 vs. 71%, p = 0.03). Logistic regression identified family history (OR: 2.4) as an independent risk factor, whereas smoking was inversely associated (OR: 0.4). Similar patterns were observed in the ASAS-fulfilling (33%) and psoriasis-excluded (36%) subgroups. At diagnosis, approximately one third of patients meet the ASAS definition of early axSpA. These patients are characterized by a higher frequency of family history, less smoking and structural damage. These results support the feasibility and relevance of future studies including patients with early axSpA to provide further scientific evidence at earlier stages of the disease.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"122"},"PeriodicalIF":3.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publication activity trends in the field of social media in rheumatology: a Web of Science-based bibliometric analysis.","authors":"Maidan Mukhamediyarov, Dana Bekaryssova","doi":"10.1007/s00296-025-05867-7","DOIUrl":"https://doi.org/10.1007/s00296-025-05867-7","url":null,"abstract":"<p><p>Social media (SoMe) is crucial in disseminating information and raising awareness about health conditions. In recent years, rheumatology specialists have increasingly utilized social networks to support and promote scientific research. This study presents a bibliometric analysis of global social media and rheumatology trends, identifying leading authors, citation patterns, and emerging research areas. The analysis used data exported from Web of Science (WoS) from 2015 to 2024. The search used MeSH-derived keywords, specifically \"social media rheumatology,\" without applying filters, covering January 2015 to December 2024 timeframe. A comprehensive search resulted in retrieving 251 publications. After ranking these publications and applying inclusion and exclusion criteria, 152 articles were included in the final analysis. A total of 152 publications were analyzed, revealing a significant positive trend in the number of publications over time (p = 0.001). The leading countries in terms of publication activity were the US (35.53%), the United Kingdom (32.24%), Australia (11.18%), Germany (9.87%), and France (9.21%). The research originated from 66 countries, but only 18 demonstrated substantial activity. The US led in scientific contributions relative to population and Gross Domestic Product (GDP). Regarding publication types, 137 (90.13%) were original research articles, while the remainder were review articles. The median citation count for original articles was 5 (range: 0-116), while review articles had a higher median citation count of 28 (range: 0-156), indicating that reviews were cited more frequently than original studies (p = 0.001). The median citation count for publications indexed in SCIE, SSCI, and ESCI was 5.5 (range: 0-116) and 6 (range: 0-116), respectively. Most publications were published in the following journals: Clinical Rheumatology (n = 25), Rheumatology Advances in Practice (n = 25), Rheumatology International (n = 16), BMJ Open (n = 12) and Journal of Medical Internet Research (n = 8). High-income countries, such as the US, the United Kingdom, and Australia, have significantly contributed to the field of social medicine in rheumatology, underscoring disparities in scientific research capacity across different regions.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"119"},"PeriodicalIF":3.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}